Anteris Technologies Initiates American Depository Receipt Program

Anteris Technologies Ltd. has established a sponsored Level 1 American Depository Receipt (ADR) program in the United States in an effort to improve U.S. investor access to Anteris ordinary shares.
 
The ADRs representing Anteris ordinary shares will trade on the over-the-counter (OTC) market. The ADR ticker symbol is ANTTY and Deutsche Bank has been appointed as the Depositary Bank for Anteris Technologies’ ADR program.
 
The company’s ADR program does not involve the issuance of new ordinary shares or the raising of new capital. ADRs will be tradeable by licensed U.S. brokers in the ordinary course of trading on the OTC market.
 
ADRs allow U.S. investors to hold shares of a foreign company without the need for cross-border or cross-currency transactions. Each ADR issued by Deutsche Bank represents an interest in one Anteris ordinary share that has been deposited with Deutsche Bank. ADRs are denominated in U.S. dollars.
 
The program intends to simplify and streamline U.S. investors’ access to investing in Anteris by eliminating the need to deal with foreign currencies or the complexities of trading on foreign stock exchanges.
 
“Establishing an ADR program through a partnership with Deutsche Bank will increase the company’s visibility and recognition among U.S. investors, analysts, and financial media,” Anteris CEO Wayne Paterson said. “This exposure will raise awareness about the company and our DurAVR technology with key stakeholders in the world’s largest capital market. The program will broaden our shareholder base, increasing trading volumes and liquidity and attracting more institutional investors. The program will also further support our commercial strategy in delivering greater value to our shareholders.”
 
DurAVR is a transcatheter heart valve (THV) used to treat aortic stenosis. DurAVR THV has been designed in partnership with interventional cardiologists and cardiac surgeons and is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy, human aortic valve. DurAVR THV is made using ADAPT tissue, Anteris’ patented, anti-calcification tissue technology that has been used clinically for more than 10 years and distributed for use in over 50,000 patients worldwide. The ComASUR Delivery System is designed to provide controlled deployment and accurate placement of the DurAVR THV with balloon-expandable delivery, allowing precise alignment with the heart’s native commissures to achieve desired valve positioning.

Anteris Technologies Ltd. is a structural heart company that designs, develops, and commercializes medical devices. Founded in Australia with a significant presence in Minneapolis, Anteris is science driven, with an experienced team of multidisciplinary professionals delivering solutions to structural heart disease patients.